Compare Estee Lauder Companies Inc (EL) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Estee Lauder Companies Inc trades at $102.09 (market cap $36.81B), while GE HealthCare Technologies Inc. Common Stock trades at $69.47 (market cap $30.93B). The key difference: Estee Lauder Companies Inc is the larger of the two by market cap, and Estee Lauder Companies Inc pays the higher dividend (1.38%). Which is the better fit depends on your goals.
| EL | GEHC | |
|---|---|---|
Market Cap | $36.81B | $30.93B |
Volume | 2,214,573 | 5,033,451 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $88.16 |
52-Week Low | $67.23 | $59.48 |
Typical Hold Time | 123 Days | — |
Enterprise Value | $42.56B | $39.39B |
Dividend Yield | 1.38% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $99.73, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company shows mixed fundamentals with a high P/E ratio of 199.46 but strong gross margins of 75.5%. Recent earnings beats and a strategic AI partnership with Profound highlight operational momentum, though 2025 saw a net loss of $1.13B. Analyst consensus is positive with a $103 price target and 48% buy ratings.
The outlook remains cautiously optimistic as EL navigates margin recovery and digital transformation. Key opportunities include brand innovation and AI integration, while risks involve persistent profitability challenges and competitive pressures. The stock's current level near resistance at $102 suggests near-term consolidation potential.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
